Advertisement
UK markets open in 5 hours 27 minutes
  • NIKKEI 225

    38,296.08
    +743.92 (+1.98%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • CRUDE OIL

    83.31
    -0.05 (-0.06%)
     
  • GOLD FUTURES

    2,334.60
    -7.50 (-0.32%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • Bitcoin GBP

    53,575.46
    -197.03 (-0.37%)
     
  • CMC Crypto 200

    1,435.30
    +20.54 (+1.45%)
     
  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

Microchip (MCHP) Q4 Earnings Beat, Revenues Miss Estimates

Microchip Technology Incorporated MCHP delivered fourth-quarter fiscal 2019 non-GAAP earnings of $1.48 per share, surpassing the Zacks Consensus Estimate by $1.39 per share. The figure was also toward the higher end of management’s guided range of $1.30-$1.49 per share and surged from $1.40 reported in the year-ago quarter.

The year-over-year upside was driven by higher net sales, which increased 32.7% from the year-ago quarter to $1.329 billion on a non-GAAP basis. However, the figure missed the Zacks Consensus Estimate of $1.337 billion. Notably, revenues were within management’s guided range of $1.279 billion to $1.375 billion.

Microchip Technology Incorporated Revenue (Quarterly)

Microchip Technology Incorporated Revenue (Quarterly) | Microchip Technology Incorporated Quote

ADVERTISEMENT

Notable Developments

Portfolio expansion across majority of the operating domains bode well. Microchip recently unveiled the first Arm-based microcontrollers (MCUs) that offer cost effective and large ecosystem based on Commercial Off-the-Shelf (COTS) technology.

The company also announced availability ofAcuEdge ZLK38AVS Development Kit for Amazon Alexa Voice Service (AVS). Moreover, the company unveiled the PolarFire FPGA imaging and solution primarily for 4K high resolutions and to support all data types, including audio, video, control and Ethernet, over a single cable.

Microchip announced availability of IEEE 802.15.4-compliant module, which integrates ultra-low-power MCU, sub-GHz RF LoRa transceiver and software stack that offers long-lasting battery life.

The company recently inked a deal withAcacia Communications Inc.'s AC1200 Coherent Module with its DIGI-G5 Optical Transport Network (OTN) processor to provide a simple and effective way to connect embedded applications.

Further, the company also introduced the latest dual- and single-core dsPIC33C Digital Signal Controllers (DSCs) to address the needs across memory, temperature and functional safety.

The company also introduced SAR ADC family to enhance the high-frequency, high resolution in regular life and work environment.

Recently, Microchip announced availability of the MPLAB Harmony version 3.0 (v3) which integrates ultra-low-power 32-bit MCU, sub-GHz RF LoRa transceiver and software stack.

The company also launched Libero SoC version 12.0 and PolarFire FPGAs.

Notably, we believe Microchip is well poised to capitalize on Microsemi’s growth catalysts. Apart from a robust portfolio, the buyout is likely to expand Microchip’s total addressable markets. Strong demand for Microsemi’s solutions in Data Center, Communications, Defense & Aerospace markets is likely to aid Microchip’s long-term growth prospects.

The company is benefiting from robust demand for 8-bit, 16-bit and 32-bit microcontrollers. We believe that Microchip's expanding product portfolio driven by new launches will continue to expand customer base.

Margins

Microchip reported non-GAAP gross margin of 62.2%, expanding 50 bps on a year-over-year basis.

Non-GAAP operating expenses, as percentage of revenues, were up 360 bps year over year to 25.8%. The increase was primarily due to higher research & development (R&D) and selling, general & administrative (SG&A) expenses.

Consequently, non-GAAP operating margin contracted 310 bps from the year-ago quarter to 36.4%.

Balance Sheet & Cash Flow

The company exited the quarter under review with $430.9 million of cash and short-term investments as compared with $436.2 million reported in the previous quarter. Total debt (long plus current portion) amounted to $10.31 billion as compared with $10.54 billion in the previous quarter.

Notably, the company paid $277.5 million of total debt during the quarter.

The company announced a quarterly cash dividend of 36.55 cents per share, payable on Jun 4, 2019.

Guidance

Microchip forecasts first-quarter fiscal 2020 net sales of $1.26-$1.40 billion (mid-point $1.33 billion). The Zacks Consensus Estimate for the same is pegged at $1.39 billion.

For the first quarter, non-GAAP earnings are anticipated in the range of $1.26-$1.49 per share (mid-point $1.375 billion). The Zacks Consensus Estimate for the same is pegged at $1.57 per share.

Non-GAAP gross margin is anticipated in the range of 61.8-62.2%. Non-GAAP operating expenses, as percentage of sales, are projected at 25.3-26.3%, and operating margin is expected at 35.5-36.9%.

Microchip's inventory days in the impending quarter are expected between 120 and 139 days. Capital expenditures is estimated to be $35 million.

For fiscal 2020, capital expenditures are projected to be in the range of $130 million and $150 million.

Zacks Rank & Key Picks

Microchip carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader technology sector are Cirrus Logic, Inc. CRUS, Universal Display Corporation OLED  and Synopsys, Inc. SNPS, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Cirrus Logic, Universal Displayand Synopsyshave a long-term earnings growth rate of 15%, 30% and 10%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Synopsys, Inc. (SNPS) : Free Stock Analysis Report
 
Cirrus Logic, Inc. (CRUS) : Free Stock Analysis Report
 
Universal Display Corporation (OLED) : Free Stock Analysis Report
 
Microchip Technology Incorporated (MCHP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research